

1 **Real-World COVID-19 Vaccine Protection Rates against In-** 2 **fection in the Delta and Omicron Eras**

3 Yuru Zhu¹, Jia Gu¹, Yumou Qiu^{2,*} & Song Xi Chen^{1,3,*}

4 ¹*Center for Statistical Science, Peking University.*

5 ²*Department of Statistics, Iowa State University.*

6 ³*School of Mathematical Science and Guanghua School of Management, Peking University.*

7 **The real-world protection rates of vaccination (VPRs) against the SARS-Cov-2 infection are**
8 **critical in formulating future vaccination strategies against the virus. Based on a varying co-**
9 **efficient stochastic epidemic model, we obtain seven countries' real-world VPRs using daily**
10 **epidemiological and vaccination data, and find that the VPRs improved with more vaccine**
11 **doses. The average VPR of the full vaccination was 82% (SE: 4%) and 61% (SE: 3%)**
12 **in the pre-Delta and Delta-dominated periods, respectively. The Omicron variant reduced**
13 **the average VPR of the full vaccination to 39% (SE: 2%). However, the booster dose re-**
14 **stored the VPR to 63% (SE: 1%) which was significantly above the 50% threshold in the**
15 **Omicron-dominated period. Scenario analyses show that the existing vaccination strategies**
16 **have significantly delayed and reduced the timing and the magnitude of the infection peaks,**
17 **respectively, and doubling the existing booster coverage would lead to 29% fewer confirmed**
18 **cases and 17% fewer deaths in the seven countries compared to the outcomes at the existing**
19 **booster taking rates. These call for higher full vaccine and booster coverage for all countries.**

*corresponding authors

20 The SARS-Cov-2 has been circulating globally with a sequence of emerging variants since
21 the start of the pandemic. Particularly, the Delta and Omicron variants have contributed to surges
22 in the infected cases across the globe due to their high transmissibility^{1,2}. To prevent the spread
23 of COVID-19, vaccines have been rolled out since later 2020, while the booster shots were started
24 since June 2021. Clinical trials or observational studies have been made to evaluate the effects
25 of a vaccine or an arrangement of mixed vaccines³⁻⁹. It is found that the vaccine efficacies of
26 the two-dose vaccination against the original SARS-Cov-2 strain ranged from 50.7% to 95%^{3,4,10},
27 but waned against Delta and Omicron variants. The vaccine effectiveness ranged from 82.8% to
28 94.5% against Delta and 48.9%-75.1% against Omicron for two doses of Pfizer, AstraZeneca or
29 Moderna vaccines⁸. The vaccine efficacy is defined as one minus the relative risk in the randomized
30 controlled clinical trials¹¹, and the vaccine effectiveness is valued in observational studies, which is
31 one minus the hazard ratio in cohort studies⁶ and one minus the odds ratio in case-control studies⁵.
32 Observational studies were more common in the Omicron era.

33 The booster dose had been shown to increase protection against infection. For homologous
34 or heterologous booster doses of Pfizer, AstraZeneca and Moderna, the effectiveness was 82.3%-
35 97.0% against Delta and 55.6%-73.9% against Omicron, with higher effectiveness using Moderna
36 as the heterologous booster dose⁸. The vaccine effectiveness was 51.0% for three doses of Sinovac
37 against Omicron¹², which increased to 63.6% by Sinovac as primary with one Pfizer booster¹³.
38 See Table S1 in the supplementary for the detailed vaccine efficacy and effectiveness discovered by
39 the existing clinical and observational studies. However, the real-world performance of vaccines
40 at the country's population level which we call the vaccine protection rate is largely unknown.

41 Different from vaccine efficacy and effectiveness, the real-world vaccine protection rate
42 (VPR) is defined as one minus the percentage reduction in the infection rate of the vaccinated rel-
43 ative to the unvaccinated population of a country. The VPR measures the combined effectiveness
44 of vaccines administrated in a country at a particular age distribution and nonpharmaceutical in-
45 tervention measures against COVID-19. The impacts of these factors are not necessarily evaluated
46 in the homogeneous clinical trials, cohort studies or case-control studies. Indeed, the conventional
47 vaccine efficacies are pegged to a specific vaccine or a mix of vaccines in the clinical trials after ex-
48 cluding certain part of the population, which may not conform to the population characteristics of
49 the country. Therefore, the available vaccine efficacy or effectiveness does not necessarily reflect
50 the vaccine immunity level of the whole population against different variants of the SAR-COV-2
51 virus. Hence, it is useful to obtain the real-world VPRs of a country.

52 Using the daily epidemiological and vaccination data, which include the cumulative numbers
53 of confirmed cases, deaths, recoveries, and people having received the partial, full and booster vac-
54 cination, we construct a varying coefficient stochastic epidemic model with eleven compartments
55 (flow diagram in Figure 4) and develop an estimation procedure for the real-world VPRs as well
56 as the key parameters quantifying the dynamic infection, death and recovery rates, which compre-
57 hensively reflects the COVID-19 dynamics and nonpharmaceutical interventions (NPI). Compared
58 with existing studies on the effect of vaccination^{14,15}, we do not assume permanent and full immu-
59 nity of the vaccines and previous infection while incorporating the stochastic natures of the epi-
60 demics with time-varying infection rate due to varying levels of NPI and self protective measures,
61 and allow asymptomatic infection, infection before clinic confirmation, vaccine breakthrough, re-

62 infection and different levels of immunity induced by different vaccine doses. The non-parametric
63 time-varying infection rate in our model is better suited for the COVID-19 pandemic as both the
64 virus transmission rate and the NPI measures change over time.

65 We considered seven countries that are representative for different types of vaccines with
66 sufficient number of confirmed cases (more than 10% of the total population) after vaccination.
67 Specifically, the results of the US may be used to show the effect of mRNA vaccines (Pfizer
68 and Moderna); the three European countries, UK, Italy and Germany, mainly used a mixture of
69 non-replicating viral vector vaccines (AstraZeneca) and mRNA vaccines; the two south American
70 countries, Brazil and Peru, utilized the inactivated vaccines (Sinopharm and Sinovac), AstraZeneca
71 and Pfizer; Turkey used the inactivated vaccines at the beginning and then started Pfizer. In this
72 paper, the full dose means one dose for Janssen and two doses for the other brands to complete the
73 primary vaccination. Those who have not completed the full vaccination are called partially vac-
74 cinated. The booster shot means one dose after full vaccination. The coverage rates of the partial,
75 full and booster vaccines in population are reported in Figure 3 (a), which shows 62.3%–79% of
76 the population in the seven countries have taken the full shots on March 15 2022, but the coverage
77 rates of booster shots were much lower, ranging between 29.1% in the US and 63.4% in Italy.

78 **Results**

79 For each country, we estimate the vaccine protection rates in six consecutive non-overlapping post-
80 vaccine periods: the pre-Delta, Intervening I, Delta-dominated, pre-Omicron, Intervening II and

81 Omicron-dominated periods. Details of these periods are provided in the method section.

82 **Vaccine protection rates.** The real-world VPRs for the partial, full and booster vaccination in the
83 seven countries in the six post-vaccine periods are reported in Figure 1 with detailed numerical val-
84 ues in Table S3. It shows that before the booster vaccination, both the partial and full vaccination
85 were largely protective against the COVID infection in the pre-Delta period with the VPRs in the
86 seven countries ranging 48%-64% and 68%-95% for the partial and full vaccination, respectively.
87 However, the Delta variant had caused waning VPRs of the partial and full vaccination. Specifi-
88 cally, the average VPR of the partial vaccination decreased from 57% (SE: 2%) in the pre-Delta
89 period to 40% (SE: 2%) in the Delta-dominated period, suggesting that only the partial shot was
90 insufficient to protect against the Delta variant. Despite the Delta-variant also reduced the average
91 VPR of the full dose from 82% (SE: 4%) in the pre-Delta period to 61% (SE:3%) in the Delta-
92 dominated period, the average VPR of the full vaccination still stayed above the WHO recognized
93 50% level of vaccine efficacy in most countries except Turkey (Figure 1). The coming of Omicron
94 had reduced the VPRs of the partial and full vaccination in the seven countries to less than 50%.
95 In the Intervening II period, the VPRs were 5.5%-34% (Average: 22.2%, SE: 4.0%) for partial
96 vaccination, and 37%-56% (Average: 49.1%, SE: 2.3%) for full vaccination. When the Omicron
97 variant became prevalent, VPRs were even lower, which were 3.8%-28.5% (Average: 11.5%, SE:
98 3.3%) and 26%-45% (Average: 38.6%, SE: 2.4%) for the partial and full vaccination, respectively.

99 The booster shot was started in the pre-Omicron period when the Delta was dominant. Our
100 study shows that it readily restored the VPRs to 78.8%-97% (Average: 83.3%, SE: 2.3%), which




Figure 1: Estimated vaccine protection rates of partial, full and booster vaccination in the seven countries over the six periods with the 95% confidence interval bars. The vaccines used are reported in the parentheses (AZ: AstraZeneca, JS: Janssen, MD: Moderna, NV: Novavax, PZ: Pfizer, SNP: Sinopharm, SNV: Sinovac, TKV: Turkovac).

101 means that the booster vaccination's VPRs were 20.5%-31.8% (Average: 26.8%, SE: 1.2%) higher
102 than those of the full vaccination against the Delta variant. In the Omicron-dominated period, the
103 booster shot's VPRs ranged 55.6%-67.0% (Average: 63%, SE: 1.4%), largely stayed above the
104 50% threshold. These suggest that the booster shot provided enhanced and effective protection
105 against both the Delta and Omicron variants.

106 **Impacts of Full and Booster Vaccines.** To further evaluate the protection of the COVID-19 vac-
107 cination, we investigate the impacts of the full and the booster vaccination on the size of the epi-
108 demics and deaths. Five vaccination scenarios were designed: (i) no vaccination at all; (ii) receiv-
109 ing the partial but no full vaccination; (iii) receiving the partial and full vaccination but no booster
110 shots; receiving the booster shots only at the half (iv) and twice (v) of the actual daily booster
111 coverage rates. The impacts of these scenarios were projected using the stochastic epidemic model
112 with the estimated parameters for each country. See the specific designs of the scenario analysis
113 (SA) in Section S5 of the supplementary material (SM).

114 The projected cumulative confirmed cases and deaths from the start of vaccination to the start
115 of boosters for the seven countries under the no vaccination (i) and only the partial vaccination (ii)
116 scenarios are shown in Figure 2 (a) and (b) with the detailed numerical values listed in Table S4. It
117 shows that no vaccination at all would bring, respectively, 112918 (CI: 96142-129695, Percentage:
118 242%) and 825 (CI: 630-1020, Percentage: 83%) thousands increase in the cumulative confirmed
119 cases and deaths in the seven countries relative to the observed values under the actual vaccination
120 arrangement. Under the only partial vaccination, the cumulative confirmed cases and deaths would




Figure 2: Radar plots on the proportions of the projected cumulative numbers of confirmed cases and deaths under two sets of scenario analyses (SA): the pre-booster vaccine periods under no and partial vaccination (a, b) and the post-booster periods under the no, half and twice booster up-take scenarios (c, d), relative to their respective observed values in the seven countries. The 100% gray dashed circles represent the observed situations.

121 increase by 39697 (CI: 30105-49289, Percentage: 85%) and 218 (CI: 124-312, Percentage: 22%)
122 thousands, respectively, in the seven countries. These two scenario analyses show the significant
123 benefit of the partial and the full vaccination.


124 The less amount of increase in the confirmed cases and deaths under the no and partial
125 vaccination scenarios in Peru was due to its low and slow pace of vaccination, with only 6% and
126 3% of the population having received the partial and full vaccination within the first 100 days
127 of vaccination. In contrast, 13.4%-18.9% and 5.5%-13.9% of the populations had been partially
128 and fully vaccinated in Germany, Italy, Brazil and Turkey, and the US and UK had the highest
129 vaccination rates of 27.7%-48.1% and 15.5%-15.9% for the partial and full vaccination over the
130 same period (Figure 3 (a)). That US and UK had the highest vaccination rates in the first 100 days
131 led to much higher numbers of cases and deaths under the no and partial vaccination scenarios in
132 Figure 2 (a) and (b), as compared with the other countries.

133 Figure 2 (c) and (d) display the projected cumulative confirmed cases and deaths from the
134 start of booster shots to March 15, 2022 under the scenarios (iii)-(v) regarding the booster vacci-
135 nation which kept the observed numbers of the partial and full doses as the baselines; see Table
136 S5 for the detailed numerical values. It is shown that during the post-booster periods, not having
137 the booster shots at all would mean 34860 (CI: 23543-46177) and 143 (CI: 88-198) thousands
138 more confirmed cases and deaths, respectively, in the seven countries, amounting to 36% and 26%
139 increases in the total confirmed cases and deaths, respectively. In the half-booster scenario, the
140 increases in the confirmed cases and deaths would be less than those under the no-booster case, but

141 still translate to 14587 (CI: 8024-21150, Percentage: 15%) and 66 (CI: 29-103, Percentage: 12%)
142 thousands more confirmed cases and death relative to the observed numbers, respectively, for the
143 seven countries in the post-booster period.

144 If the booster taking rates were doubled, we see decreases of 27679 (CI: 21234-34124, Per-
145 centage: 29%) and 94 (CI: 62-126, Percentage: 17%) thousands in total confirmed cases and deaths
146 for the seven countries in the post-booster period. It is noted that the relatively large reductions in
147 the confirmed cases and deaths in Germany, Italy, Turkey and UK under the double booster sce-
148 nario were due to their actual higher (more than 40%) rates of taking the booster shots by March
149 15, 2022 (Figure 3 (a)). In contrast, the US, Brazil, Peru had lower booster taking rates, which
150 led to smaller amount of reductions in the confirmed cases and deaths as compared to the other
151 countries.

152 To further evaluate the dynamics of the COVID-19 epidemics with respect to different vacci-
153 nation strategies, we report in Figure 3 (b) the observed and the projected daily numbers of active
154 confirmed cases (those confirmed infective people who have not recovered or died), to reflect the
155 potential real-time demand on the hospital system under the five scenarios. It shows that, compared
156 to the observed time series of the active confirmed cases, the peaks of the active confirmed cases
157 would be much elevated and happen much earlier under the no and partial vaccination scenarios.
158 In particular, the numbers of active confirmed cases in Germany, Italy, Turkey, the UK and the US
159 would peak when the Delta was dominant. It also shows that the full and the booster shots signifi-
160 cantly delayed the timing and flattened the magnitude of the infection peaks in the seven countries,



(b) Active confirmed cases




Figure 3: (a) Daily population proportions receiving at least one (red), full (blue) and booster (green) dose of vaccines. The dashed vertical lines mark March 15 and July 17, 2022. (b) The actual (black dashed lines), and the projected daily numbers (in millions) of active confirmed cases (color curves) and their 95% confidence bands (color area) under the five vaccination scenarios.

161 and in particular, protected the populations in the more lethal pre-Omicron era. As shown in Table
162 S6, the projected numbers of active confirmed cases would exceed the observed peaks for 70-111,
163 65-156, 23-59 and 0-42 days with the projected peaks being 1.7-9.4 (Mean 4.1, SE 1.1), 1.2-7.0
164 (Mean 3.5, SE 0.9), 1.2-1.8 (Mean 1.4, SE 0.06) and 1.0-1.3 (Mean 1.1, SE 0.04) times the ob-
165 served peaks under the no vaccination, partial vaccination, no booster and half booster scenarios,
166 respectively. Those indicate the effect of the vaccination potentially avoided severe runs on the
167 health system of the seven countries.

168 Comparing the actual observations with the three scenarios regarding the booster shot taking,
169 the peak values of active confirmed people in the seven countries would increase by 23%-78%
170 (Mean: 43%, SE: 6%) under the no booster scenario, and decrease by 26%-63% (Mean: 41%,
171 SE: 5%) relative to the observed peaks under the twice booster scenario, which verifies the booster
172 does can further relieve the pressure on the healthcare system in the Omicron era due to its higher
173 VPRs against the Omicron variants as reported in Figure 1.

174 It is noted that in Italy the projected peak under the partial vaccination scenario was higher
175 than that under the no vaccination in the Intervening II period. This was due to that a considerable
176 proportion of population would have been infected in the Delta-dominated period under the no vac-
177 cine scenario, and Italy had the highest rate of partial vaccination before the Intervening II period
178 among the seven countries (Figure 3 (a)). However, the immunity acquired from the partial vacci-
179 nation gradually expired without further injected immunity from the full dose. This would lead to a
180 rebound in the numbers of susceptibles, even exceeding those under the no vaccination scenario as

181 shown in Figure S1. This result suggests the importance of acquiring additional immunity through
182 full and booster doses.

183 **Discussion**

184 This study targets the population protection rates of vaccines. Although the vaccine efficacies are
185 different between different age groups, our results reveal the overall protection rates of a country,
186 which are informative on the total infection size and the demand on the health resources of a coun-
187 try. It is shown that the real-world vaccine protection rates (VPRs) of the partial, full and booster
188 vaccination decreased with time. The full vaccination was effective before Omicron with the VPRs
189 stayed above 50%, which became insufficient when the Omicron was dominant. The booster shot
190 was effective in slowing down the epidemics in both the Delta and Omicron-dominated periods
191 with the average VPRs well above the 50% threshold. Our results on the real-world VPRs were
192 consistent with the vaccine effectiveness in the existing cohort or case-control studies^{9,12,16}. The
193 necessity of the full and the booster vaccination are further highlighted by significant reductions in
194 daily numbers of active confirmed cases in the scenario analyses.

195 Two sets of sensitivity analyses have been conducted to explore the impact of the uncertainty
196 associated with model parameters for the daily asymptomatic rate $1 - \theta_t$ and the average time
197 duration μ_r from recovery to loss of natural immunity (average duration for reinfection) on the
198 estimated VPRs. The sensitivity analyses show that the average absolute differences between the
199 VPRs by using different values of the daily asymptomatic rate and the average duration for rein-

200 fection were 1.26% (SE: 0.23%) and 0.94% (SE: 0.17%), respectively, indicating the robustness of
201 the estimated VPRs with respect to the two key parameters.

202 Despite the effectiveness of the booster shot in the Omicron era, the booster vaccine coverage
203 had a rather slow pace of growth with less than 9% increase from March 15 2022 to July 17 2022
204 in Italy, Turkey, the UK and the US, as shown in Figure 3 (a). The booster coverage was 37.6%
205 on July 17, 2022 in the US, which was only increased by 8.5% over the four months since March
206 15 2022, and the UK's increased only 3.1% over the same period. Thus, there is ample room
207 for vigorous promotion of booster shots in all countries to realize their benefits in reducing both
208 the size of the epidemics and death. The encouraging effects of the booster shots also encourage
209 consideration for another dose after the booster shot to cope with the continuing evolution of the
210 SARS-Cov-2 viruses.

211 **Methods**

212 The study period in this research is from the start of the vaccine in a country to March 15, 2022,
213 while part of the pre-vaccine period was considered for model parameter estimation. For each
214 country, we divide the post-vaccine era into six consecutive non-overlapping periods: the pre-
215 Delta period from the start of vaccination till the Delta variant was first detected in the country, the
216 following intervening period (Intervening I) until the Delta variant became predominant (more than
217 50% of the daily detected cases), the Delta-dominated period when the majority of the cases were
218 caused by the Delta variant till the start of booster shots, the pre-Omicron period from the start
219 of booster shots till the Omicron variant was first detected, the intervening period (Intervening II)

220 till Omicron became predominant, the Omicron-dominated period when the majority of the cases
 221 were caused by the Omicron variant. It is noted that the dominated variant was still Delta in the
 222 pre-Omicron period in the seven countries. Since the start of the booster shot (June 21, 2021) was
 223 close to the date (June 29, 2021) when the Delta variant began to dominate in Turkey, we merged
 224 its Delta-dominated period and pre-Omicron period, which makes Turkey have only five periods.
 225 The key dates of these periods are provided in Table S2 in the SM.

226 We estimate the real-world VPR by building a stochastic epidemiological model with eleven-
 227 compartments to quantify the epidemic process and developing a novel estimation procedure for
 228 its parameters.




Figure 4: Compartments and their structure flows of the proposed epidemiological model, where the compartments V_0 and V_e constitute state $S = V_0 + V_e$ of currently uninfected people without immunity, and ϕ_1 , ϕ_2 and ϕ_3 are the parameters representing vaccine protection rates.

229 **Stochastic epidemiological model.** The stochastic epidemiological model describes the spread
230 of the SARS-CoV-2 virus and the daily increase of infected cases in a country. The compart-
231 ments and flows between compartments are shown in Figure 4. The model allows non-permanent
232 vaccine and natural immunity, breakthroughs in vaccinated people, and being asymptomatic and
233 infectious before clinical diagnosis (pre-symptomatic). The susceptible population are divided into
234 five compartments, the ones with no, partial, full and booster vaccine immunity and the ones who
235 have been vaccinated but lost vaccine immunity or have recovered from previous infection but
236 lost natural immunity, in the top row of Figure 4. The currently uninfected compartment without
237 vaccine or natural immunity consists of unvaccinated people, the vaccinated people with expired
238 vaccine immunity and the recovered with expired natural immunity; see the SM for the specific ar-
239 rangement on the vaccine expiration parameters μ_1 , μ_2 and μ_3 , and the parameter of losing natural
240 immunity μ_r . The latter is responsible for reinfection. The uninfected individuals may catch the
241 virus by contacting with the infected which are divided into three compartments: asymptomatic,
242 pre-symptomatic and diagnosed. Asymptomatic cases represent the ones show no symptoms and
243 do not take a test. The pre-symptomatic period stands for the period after infection but before lab
244 confirmation. The pre-symptomatic cases would be diagnosed at the rate $\alpha \in (0, 1)$, where $1/\alpha$
245 represents the average days between being infected and lab diagnosis.

246 Following the set up of the infection rates for different stages of infections¹⁷, we assume the
247 pre-symptomatic compartment is five times more infectious than the asymptomatic and diagnosed
248 compartments, as diagnosed cases would take precautions and quarantine at home, and asymp-
249 tomatic cases have no symptoms and should be less infectious. Let M be the total population size,

250 β_t denote the time-varying infection rate of the pre-symptomatic cases, and $\tilde{I}(t)$ be the standard-
251 ized total infection load, which is equal to the size of the pre-symptomatic compartment divided by
252 M plus those of the asymptomatic and diagnosed compartments divided by $5M$. Allowing time-
253 varying infection rate (β_t) is needed as government and citizens' responses to COVID-19 change
254 over time and the virus itself keeps mutating. We assume the daily new infections from the sus-
255 ceptible groups without vaccine or natural immunity, and with partial, full and booster vaccine im-
256 munity follow conditional Poisson distributions with means equal to $\beta_t \tilde{I}(t)$, $\varphi_1 \beta_t \tilde{I}(t)$, $\varphi_1 \varphi_2 \beta_t \tilde{I}(t)$
257 and $\varphi_1 \varphi_2 \varphi_3 \beta_t \tilde{I}(t)$ multiplying the size of the corresponding group, respectively, which are shown
258 in Figure 4. And a new infection has $1 - \theta_t$ probability being asymptomatic, which is modelled
259 by a binomial distribution. The specification of θ_t is given in the SM, which is based on exist-
260 ing studies¹⁸⁻²⁰ on the proportion of asymptomatic cases over different periods of the pandemic.
261 The vaccine effects are reflected by $\varphi_1, \varphi_2, \varphi_3 \in (0, 1)$, where the individuals having partial, full
262 and booster vaccine immunity are less likely being infected comparing to the those without vac-
263 cine immunity by the factors $\varphi_1, \varphi_1 \varphi_2$ and $\varphi_1 \varphi_2 \varphi_3$, respectively. The VPRs for the three vaccine
264 compartments are $1 - \varphi_1, 1 - \varphi_1 \varphi_2$ and $1 - \varphi_1 \varphi_2 \varphi_3$, respectively.

265 **Estimation.** Given the above model arrangement, we estimate the diagnosis rate α , time-varying
266 infection, recovery and death rates, and the VPR parameters φ_1, φ_2 and φ_3 of a country by a multi-
267 step multi-time range procedure via minimizing certain criterion functions using different periods
268 of data for different variants of SARS-CoV-2 virus, and a nonparametric regression method for the
269 time-varying parameters.

270 The recovery and death rates are estimated by the kernel smoothing regression of daily new

271 recovery and death numbers on the total size of active confirmed infections at time t . If the recovery
272 data are not available, we set it as $1/14$, meaning 14 days as the average recovery time since
273 diagnosis²¹. Let $I_p(t)$ be the size of the pre-symptomatic compartment and $\Delta N(t)$ be the new
274 confirmed cases at day t . Adopting a multi-step estimation procedure, we use the B-splines to fit the
275 infection rate β_t , and minimize the criteria function $\sum_{t \in \mathcal{S}} \left\{ \alpha \hat{E}^{\alpha, \varphi_1, \varphi_2, \varphi_3} \{I_p(t) | \mathcal{F}_{t-1}\} / \Delta N(t) - 1 \right\}^2$
276 with respect to α , φ_1 , φ_2 , φ_3 and the coefficients of the B-splines over an estimation period \mathcal{S} .
277 Here $\Delta N(t)/\alpha$ stands for an imputation for $I_p(t)$ and $\hat{E}^{\alpha, \varphi_1, \varphi_2, \varphi_3} \{I_p(t) | \mathcal{F}_{t-1}\}$ is a simulation-
278 based estimate of the conditional expectation of $I_p(t)$ given data up to $t - 1$ by averaging the
279 simulated trajectories under the proposed model at each α , φ_1 , φ_2 , φ_3 and β_t . This estimation
280 approach can be viewed as a minimum distance method that minimizes the distance between the
281 trajectories implied by the model and the observed data of daily new confirmed cases. However,
282 due to the unobservable compartments, imputation is needed as well as a decentralized strategy
283 that estimates different parameters over different time periods. The mathematical expressions of
284 the proposed model and the detailed estimation procedure are provided in the SM.

285 **Sensitivity analysis.** The number of reported cases are influenced by the severity of symptoms,
286 public willingness to do testing and the testing capacity. These factors determine the pre-symptomatic
287 proportion θ_t and the diagnosis rate α of the pre-symptomatic cases in our model. While α is em-
288 pirically estimated by the proposed method, θ_t is determined from existing studies. Murray et al.
289 (2022)²⁰ suggested the asymptomatic cases accounted for 80-90% of COVID-19 infections in the
290 Omicron era. In the main analysis, the probability for new infections being asymptomatic since the
291 detection of Omicron variant was assumed to increase linearly from 40% to 90%. To explore the

292 sensitivity of this specification, we conducted a sensitivity analysis which assumed the probability
293 of being asymptomatic for new infections after the Omicron increased linearly from 40% to 80%.
294 The estimated VPRs in the intervening II and the Omicron-dominated periods for the seven coun-
295 tries are reported in Table S7, which shows that the magnitude of the differences between VPRs
296 by altering the daily asymptomatic rates $1 - \theta_t$ was no more than 8.6% and the average of the
297 absolute differences was 1.26% (SE: 0.23%). We have also conducted a sensitivity analysis on the
298 estimated VPRs with respect to μ_r , the time duration from recovery to loss of natural immunity.
299 It shows that the differences between the estimated VPRs in the seven countries with μ_r being 16
300 months as in the main analysis and those with μ_r being 6 months were at most 5% apart with the
301 average absolute differences being 0.94% (SE: 0.17%). Table S7 contains the details for the two
302 sets of sensitivity analyses.

303 **Reporting summary.** Further information on research design is available in the Nature Research
304 Reporting summary linked to this article.

305 **Data availability**

306 The daily epidemiological and vaccination data that support the findings of this study are available
307 in a public repository “Our World in Data”, [[“https://covid.ourworldindata.org/”](https://covid.ourworldindata.org/)].

308 **Code availability** The codes used in this study are available on GitHub at [https://github.](https://github.com/zyrstat/Estimating-VPRs)
309 [com/zyrstat/Estimating-VPRs](https://github.com/zyrstat/Estimating-VPRs).

- 310 1. Viana, R., Moyo, S., Amoako, D. G. *et al.* Rapid epidemic expansion of the sars-cov-2 omicron
312 variant in southern africa. *Nature* **603**, 679–686 (2022).
- 313 2. Planas, D., Veyer, D., Baidaliuk, A. *et al.* Reduced sensitivity of SARS-CoV-2 variant Delta
314 to antibody neutralization. *Nature* **596**, 276–280 (2021).
- 315 3. Polack, F. P., Thomas, S. J., Kitchin, N. *et al.* Safety and efficacy of the BNT162b2 mRNA
316 Covid-19 vaccine. *New England Journal of Medicine* **383**, 2603–2615 (2020).
- 317 4. Voysey, M., Clemens, S. A. C., Madhi, S. A. *et al.* Safety and efficacy of the ChAdOx1
318 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
319 controlled trials in Brazil, South Africa, and the UK. *The Lancet* **397**, 99–111 (2021).
- 320 5. Bernal, J. L., Andrews, N., Gower, C. *et al.* Effectiveness of Covid-19 vaccines against the
321 B.1.617.2 (Delta) variant. *New England Journal of Medicine* **385**, 585–594 (2021).
- 322 6. Tartof, S. Y., Slezak, J. M., Fischer, H. *et al.* Effectiveness of mRNA BNT162b2 COVID-19
323 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort
324 study. *The Lancet* **398**, 1407–1416 (2021).
- 325 7. Patalon, T., Saciuk, Y., Peretz, A. *et al.* Waning effectiveness of the third dose of the
326 BNT162b2 mRNA COVID-19 vaccine. *Nature Communications* **13**, 3203 (2022).
- 327 8. Andrews, N. *et al.* Covid-19 vaccine effectiveness against the omicron (b.1.1.529) variant.
328 *New England Journal of Medicine* **386**, 1532–1546 (2022).

- 329 9. Yoon, S. K., Hegmann, K. T., Thiese, M. S. *et al.* Protection with a third dose of mrna vaccine
330 against sars-cov-2 variants in frontline workers. *New England Journal of Medicine* **386**, 1855–
331 1857 (2022).
- 332 10. Palacios, R., Batista, A., Albuquerque, C. *et al.* Efficacy and safety of a COVID-19 inacti-
333 vated vaccine in healthcare professionals in Brazil: The PROFISCOV study. *SSRN Electronic*
334 *Journal* (2021).
- 335 11. Falsey, A. R., Sobieszczyk, M. E., Hirsch, I. *et al.* Phase 3 safety and efficacy of AZD1222
336 (ChAdOx1 nCoV-19) Covid-19 vaccine. *New England Journal of Medicine* **385**, 2348–2360
337 (2021).
- 338 12. McMenamin, M. E., Nealon, J., Lin, Y. *et al.* Vaccine effectiveness of one, two, and three doses
339 of bnt162b2 and coronavac against covid-19 in hong kong: a population-based observational
340 study. *The Lancet Infectious Diseases* (2022).
- 341 13. Cerqueira-Silva, T., de Araujo Oliveira, V., Paixão, E. S. *et al.* Duration of protection of
342 CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. *Nature*
343 *Communications* **13**, 4154 (2022).
- 344 14. Dashtbali, M. & Mirzaie, M. A compartmental model that predicts the effect of social distanc-
345 ing and vaccination on controlling covid-19. *Scientific Reports* **11**, 1–11 (2021).
- 346 15. Giordano, G., Colaneri, M., Di Filippo, A. *et al.* Modeling vaccination rollouts, sars-cov-2
347 variants and the requirement for non-pharmaceutical interventions in italy. *Nature Medicine*
348 **27**, 993–998 (2021).

- 349 16. Andrews, N., Stowe, J., Kirsebom, F. *et al.* Effectiveness of COVID-19 booster vaccines
350 against COVID-19-related symptoms, hospitalization and death in England. *Nature Medicine*
351 **28**, 831–837 (2022).
- 352 17. Yan, H., Zhu, Y., Gu, J. *et al.* Better strategies for containing COVID-19 pandemic: a study of
353 25 countries via a vSIADR model. *Proceedings of the Royal Society A* **477**, 20200440 (2021).
- 354 18. Buitrago-Garcia, D., Egli-Gany, D., Counotte, M. *et al.* Occurrence and transmission potential
355 of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and
356 meta-analysis. *PLoS medicine* **17**, e1003346 (2020).
- 357 19. Ma, Q. *et al.* Global percentage of asymptomatic sars-cov-2 infections among the tested
358 population and individuals with confirmed covid-19 diagnosis: A systematic review and meta-
359 analysis. *JAMA Network Open* **4**, e2137257–e2137257 (2021).
- 360 20. Murray, C. J. Covid-19 will continue but the end of the pandemic is near. *Lancet* **399**, 417–419
361 (2022).
- 362 21. Guan, W., Ni, Z., Hu, Y. *et al.* Clinical characteristics of coronavirus disease 2019 in China.
363 *New England Journal of Medicine* **382**, 1708–1720 (2020).

364 **Author contributions** Y.Z., Y.Q, and S.X.C designed the study and drafted the paper. Y.Z. processed the
365 data and performed the statistical analysis. Y.Z., Y.Q, and S.X.C interpreted the results of the analysis and
366 reviewed the paper. All authors revised the paper and gave final approval for the version to be submitted.

367 **Funding** This research is funded by National Natural Science Foundation of China Grants 92046021,
368 12071013 and 12026607.

369 **Competing interests** The authors declare no competing interests.

370 **Correspondence** Correspondence and requests for materials should be addressed to Song Xi Chen (
371 email:songxichen@pku.edu.cn) and Yumou Qiu (email:yumouqiu@iastate.edu).